COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Irinotecan, Capecitabine and Avastin for Metastatic Colorectal Cancer as Salvage Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00717990
Recruitment Status : Terminated (Poor Accrual)
First Posted : July 18, 2008
Last Update Posted : October 7, 2015
Information provided by (Responsible Party):
Vassilis Georgoulias, MD, University Hospital of Crete

Brief Summary:
This study will evaluate the efficacy of Irinotecan,Capecitabine and Avastin combination in patients with no response to previous treatment with 5-Fluorouracil,Leucovorin,Eloxatin and Avastin.

Condition or disease Intervention/treatment Phase
Metastatic Colorectal Cancer Drug: Capecitabine Drug: Bevacizumab Drug: Irinotecan Phase 2

Detailed Description:
The aim of this phase II study is to evaluate the efficacy of the combination XELIRI/AVASTIN in patients with mCRC, who have progressed in first line treatment with FOLFOX/AVASTIN. For AVASTIN was selected the dosing schedule of the trials TREE 1 and 2 [17], where Avastin was combined with capecitabine and oxaliplatin in a three weeks schedule and with adaptation of the dose in the 7,5 mg/kg

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 15 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Irinotecan, Capecitabine and Avastin in Patients With Metastatic Colorectal Cancer, Who Have Progressed After 1ST Line Therapy With Folfox/Avastin.
Study Start Date : April 2008
Actual Primary Completion Date : December 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 1
Drug: Capecitabine
Capecitabine 2000 mg/m2 p.o. daily, for days 1-14, every 3 weeks for 6 cycles
Other Name: Xeloda

Drug: Bevacizumab
Bevacizumab 7.5 mg/kg intravenous (IV) on day 1 every 3 weeks for 6 cycles
Other Name: Avastin

Drug: Irinotecan
Irinotecan 250 mg/m2 IV on day 1 every 3 weeks for 6 cycles
Other Names:
  • Campto
  • CPT-11

Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: up to 6 months ]

Secondary Outcome Measures :
  1. Time To Progression [ Time Frame: 1 year ]
  2. Toxicity profile [ Time Frame: Toxicity assessment on each chemotherapy ]
  3. Quality of life [ Time Frame: Assessment every two cycles ]
  4. Symptoms improvement [ Time Frame: Assessment every two cycles ]
  5. Overall Survival [ Time Frame: 1 year ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 72 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed locally advanced or metastatic colorectal cancer
  • Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors
  • ECOG performance status ≤ 2
  • Age 18 - 72 years
  • Patients who progress after 1st line therapy with FOLFOX/AVASTIN
  • Adequate liver (Bilirubin ≤ 1.5 upper normal limit, SGOT/SGPT ≤ 4 upper normal limit, ALP ≤ 2.5 upper normal limit) renal (Creatinine ≤ 1.5 upper normal limit) and bone marrow (ANC ≥ 1,500/mm3, PLT ≥100,000/mm3) function
  • Patients must be able to understand the nature of this study
  • Written informed consent

Exclusion Criteria:

  • History of serious cardiac disease (unstable angina, congestive heart failure,uncontrolled cardiac arrhythmias)
  • History of myocardial infarction or stroke within 6 months
  • Clinically significant peripheral vascular disease
  • History of abdominal fistula, gastrointestinal perforation or intraabdominal abscess within 28 days prior to Day 0
  • Major surgical procedure, open biopsy, or significant traumatic injury within 30 days prior to Day 1
  • Presence of central nervous system or brain metastasis
  • Evidence of bleeding diathesis or coagulopathy
  • Blood pressure > 150/100 mmHg
  • Pregnant or lactating woman
  • Life expectancy < 3 months
  • Previous radiotherapy within the last 4 weeks or > 25% of bone marrow
  • Metastatic infiltration of the liver > 50%
  • Patients with chronic diarrhea (at least for 3 months) or partial bowel obstruction or total colectomy
  • Active infection requiring antibiotics on Day 1
  • Second primary malignancy, except for non-melanoma skin cancer and in situ cervical cancer
  • Psychiatric illness or social situation that would preclude study compliance

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00717990

Layout table for location information
University Hospital of Crete, Dep of Medical Oncology
Heraklion, Greece
Sponsors and Collaborators
University Hospital of Crete
Layout table for investigator information
Principal Investigator: Vassilis Georgoulias, MD University Hospital of Crete, Dep of Medical Oncology
Layout table for additonal information
Responsible Party: Vassilis Georgoulias, MD, MD, University Hospital of Crete Identifier: NCT00717990    
Other Study ID Numbers: CT/05.35
First Posted: July 18, 2008    Key Record Dates
Last Update Posted: October 7, 2015
Last Verified: October 2015
Keywords provided by Vassilis Georgoulias, MD, University Hospital of Crete:
Colorectal cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Antineoplastic Agents, Immunological
Antineoplastic Agents
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Antimetabolites, Antineoplastic
Molecular Mechanisms of Pharmacological Action
Topoisomerase I Inhibitors
Topoisomerase Inhibitors
Enzyme Inhibitors